BRIEF published on 12/22/2025 at 07:05, 10 months 10 days ago GenSight Biologics Receives Compassionate Use Authorization for GS010/LUMEVOQ® in France Gene Therapy Rare Diseases Compassionate Use LHON Treatment ANSM Approval
PRESS RELEASE published on 12/22/2025 at 07:00, 10 months 10 days ago Inside Information / Other news releases GenSight Biologics receives Compassionate Use Authorization in France for GS010/LUMEVOQ® gene therapy indicated for ND4-LHON treatment France GenSight Biologics GS010/LUMEVOQ® Compassionate Use Authorization ND4-LHON
BRIEF published on 11/13/2025 at 18:02, 11 months 17 days ago Heights Capital Management crosses thresholds Convertible Bonds Crossing Thresholds Shares And Voting Rights GenSight Biologics Heights Capital
BRIEF published on 10/30/2025 at 07:35, 1 year ago GenSight Biologics: Green light for compassionate treatment in the United States FDA GenSight Biologics NOHL Compassionate Access GS010/LUMEVOQ®
BRIEF published on 09/29/2025 at 23:05, 1 year 1 month ago GenSight Biologics Announces First Half 2025 Financial Results Financial Results Research And Development Treasury GenSight Biologics Early Access Programs
PRESS RELEASE published on 09/29/2025 at 23:00, 1 year 1 month ago Inside Information / News release on accounts, results GenSight Biologics reports 8.3% reduction in operating cash outflow and extends cash runway to late Q4 2025. Company's financial results show decrease in operating income, R&D expenses, and net cash flows Financial Results Operating Income Cash Management GenSight Biologics R&D Expenses
BRIEF published on 08/28/2025 at 20:05, 1 year 2 months ago GenSight Biologics Delays 2025 Half-Year Financial Results Announcement Financial Results Regulatory Compliance Postponement GenSight Biologics Audit Procedures
PRESS RELEASE published on 08/28/2025 at 20:00, 1 year 2 months ago Inside Information / Other news releases GenSight Biologics postpones the release of its 2025 half-year financial results to September 29, 2025, after the market closes, to ensure highest audit standards. No material issues reported. Audit Committee and Board meetings rescheduled Financial Results Transparency Postponement GenSight Biologics Audit Procedures
BRIEF published on 07/17/2025 at 15:05, 1 year 3 months ago GenSight Biologics: Publication of an article on the predictions of LUMEVOQ® gene therapy Gene Therapy GenSight Biologics NOHL LUMEVOQ Visual Acuity
Published on 10/30/2026 at 23:35, 1 day 16 hours ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 1 day 16 hours ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 19:00, 1 day 21 hours ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 2 days ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 11/01/2026 at 10:35, 5 hours 31 minutes ago Shenzhen Unveils APEC China 2026 Host-City Theme Song and Music Video
Published on 11/01/2026 at 05:00, 11 hours 6 minutes ago 2026 Yangtze River Culture Festival Opens in Yonglian Village, Zhangjiagang, Jiangsu
Published on 10/31/2026 at 16:35, 23 hours 31 minutes ago SKYWORTH Solar Announces Global Launch of Solavita as a Smart Microgrid Brand
Published on 10/30/2026 at 22:49, 1 day 17 hours ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 23:00, 1 day 17 hours ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 12:00, 2 days 4 hours ago Capital increase through exercise of subscription rights
